A retrospective study assessing the association between histological activity at the time of Vedolizumab initiation and outcome of therapy in patients with Ulcerative Colitis
Latest Information Update: 02 Dec 2020
Price :
$35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- 02 Dec 2020 New trial record
- 13 Oct 2020 Results presented at the 28th United European Gastroenterology Week